IP Library Granted Patent US 11,493,504
Granted Patent B2
US 11,493,504 · App. 16/851,841 · Granted Nov 8, 2022

Activation of bioluminescene by structural complementation

Inventors: Andrew S. Dixon (Verona, WI); Lance Encell (Fitchburg, WI); Mary Hall (Waunakee, WI); Keith Wood (Mt. Horeb, WI); Monika Wood (Mt. Horeb, WI); Marie Schwinn (Madison, WI); Brock F. Binkowski (Sauk City, WI); Hicham Zegzouti (Madison, WI); Nidhi Nath (Madison, WI); Subhanjan Mondal (Middleton, WI); Said Goueli (Fitchburg, WI); Poncho Meisenheimer (San Luis Obispo, CA); Thomas Kirkland (Atascadero, CA); James Unch (Arroyo Grande, CA); Dileep K. Pulukkunat (Middleton, WI); Matthew Robers (Madison, WI); Melanie Dart (Madison, WI); Thomas Machleidt (Madison, WI)
Assignee: Promega Corporation
G01N33/533A61K51/08C07K7/08C07K14/43509C12N9/0069C12Q1/66G01N33/542G01N33/581
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,493,504
App. No.
16/851,841
Granted
Nov 8, 2022
Kind
B2
Abstract

Provided herein are compositions and methods for the assembly of a bioluminescent complex from two or more non-luminescent (e.g., substantially non-luminescent) peptide and/or polypeptide units. In particular, bioluminescent activity is conferred upon a non-luminescent polypeptide via structural complementation with another, complementary non-luminescent peptide.

Claims (22)

1. A method comprising, combining:

(a) a first fusion of:

(i) a first binding moiety capable of binding to a target analyte, and

(ii) a complementary polypeptide comprising an amino acid sequence having less than 100% and greater than 40% sequence identity with SEQ ID NO: 440;

(b) a second fusion of:

(i) a second binding moiety capable of binding to a target analyte, and

(ii) a complementary peptide comprising an amino acid sequence having less than 100% and greater than 40% sequence identity with SEQ ID NO: 2;

(c) the target analyte; and

(d) a substrate for a bioluminescent complex formed between the peptide and polypeptide;

wherein a bioluminescent signal produced by the bioluminescent complex in the presence of the substrate is substantially increased when the first and second binding moieties are bound to the target analyte than in the absence of the target analyte.

2. The method of claim 1 , wherein the substrate is coelenterazine, or a coelenterazine derivative.

3. The method of claim 2 , wherein the substrate is furimazine.

4. The method of claim 1 , wherein the complementary peptide comprises an amino acid sequence having greater than 70% sequence identity with SEQ ID NO: 2271.

5. The method of claim 4 , wherein the complementary peptide comprises an amino acid sequence having 90% or greater sequence identity with SEQ ID NO: 2271.

6. The method of claim 5 , wherein the complementary peptide comprises an amino acid sequence of SEQ ID NO: 2271.

7. The method of claim 1 , wherein the complementary polypeptide comprises an amino acid sequence having greater than 70% sequence identity with SEQ ID NO: 2150.

8. The method of claim 7 , wherein the complementary polypeptide comprises an amino acid sequence having 90% or greater sequence identity with SEQ ID NO: 2150.

9. The method of claim 8 , wherein the complementary polypeptide comprises an amino acid sequence of SEQ ID NO: 2150.

10. The method of claim 1 , wherein the target analyte is a protein, small molecule, peptide, carbohydrate, nucleic acid, lipid, cell, or protein complex.

11. The method of claim 1 , wherein the first and second binding moieties are independently selected from the group consisting of: an antibody, a receptor domain that binds a target ligand, a domain of protein A, protein A, protein G, a domain of protein G, a polyclonal antibody, a monoclonal antibody, a single chain variable fragment, an antibody variable heavy chain, and an antibody variable light chain.

12. The method of claim 1 , wherein the first binding moiety and the second binding moiety are configured to bind to different epitopes on the target analyte.

13. The method of claim 1 , wherein the first binding moiety and the second binding moiety are brought into close proximity in the presence of the target analyte, thereby bringing the complementary peptide and complementary polypeptide into contact with each other.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 17, 2020
From: BINKOWSKI, BROCK F.; DIXON, ANDREW S.; ENCELL, LANCE; HALL, MARY; WOOD, KEITH; WOOD, MONIKA; SCHWINN, MARIE; ZEGZOUTI, HICHAM; NATH, NIDHI; MONDAL, SUBHANJAN; GOUELI, SAID; MEISENHEIMER, PONCHO; KIRKLAND, THOMAS; UNCH, JAMES; PULUKKUNAT, DILEEP K.; ROBERS, MATTHEW; DART, MELANIE; MACHLEIDT, THOMAS
To: PROMEGA CORPORATION
Reel/Frame 052430/0433 →
Continuity (7)
Continuation 16035117 · Jul 13, 2018
Continuation 16023972 · Jun 29, 2018
Continuation 15717534 · Sep 27, 2017
Continuation 15073249 · Mar 17, 2016
Continuation 14209610 · Mar 13, 2014
Provisional Application 61791549 · Mar 15, 2013
Related Publication 20200292534A1 · Sep 17, 2020
Cited By (2)
US 12,366,572 US 12,367,513